OBJECTIVES: We sought to investigate the vascular mechanisms of dobutamine-induced myocardial ischemia. BACKGROUND: Dobutamine stress is often used as a surrogate for exercise. The effects of dobutamine on the epicardial arteries are incompletely understood and possibly different from those of physical exercise. METHODS: Intravenous (IV) dobutamine (40 μg/kg per min) was administered in 19 patients with normal, 23 patients with mildly atherosclerotic, and 12 patients with stenotic coronary arteries. In another two groups of patients with stenotic arteries, IV dobutamine was preceded by 1) an intracoronary (IC) bolus of the alpha-adrenergic blocker phentolamine (12 μg/kg, n = 12); and 2) an IC infusion of the nitric oxide substrate L-arginine (150 μmol/l per min for 20 min, n = 11). Intravenous saline instead of dobutamine was infused into eight patients with normal arteries. After dobutamine (or saline), an IC bolus of isosorbide dinitrate (ISDN, 0.2 mg) was given. Coronary vasomotion was evaluated by quantitative coronary angiography on angiograms obtained after each dose of dobutamine, saline, phentolamine, L-arginine, and ISDN. RESULTS: Dobutamine increased the rate-pressure product and heart rate similarly in all patients except those who received saline. Dobutamine induced vasodilation in normal (change in luminal diameter [ΔLD] vs. baseline: 19 ± 2%) and in mildly atherosclerotic arteries (ΔLD: 8 ± 2%, p < 0.05 vs. normal). In stenotic arteries, dobutamine did not induce significant vasomotion (ΔLD: -3 ± 3%); the latter was improved by L-arginine (ΔLD: 10 ± 3%, p < 0.05 vs. stenotic arteries) and fully restored by phentolamine (ΔLD: 19 ± 3%, p < 0.05 vs. stenotic arteries). CONCLUSIONS: Endothelial dysfunction and enhanced alpha-adrenergic tone contribute to the loss of dobutamine-induced vasodilation in coronary atherosclerosis. In contrast to physical exercise, dobutamine does not induce "paradoxical vasoconstriction" of atherosclerotic coronary arteries. © 2003 by the American College of Cardiology Foundation.

Effects of Intravenous Dobutamine on Coronary Vasomotion in Humans / Barbato, Emanuele; Bartunek, J; Wyffels, E; Wijns, W; Heyndrickx, Gr; De Bruyne, B.. - In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. - ISSN 0735-1097. - 42:9(2003), pp. 1596-1601. [10.1016/j.jacc.2003.03.001]

Effects of Intravenous Dobutamine on Coronary Vasomotion in Humans

BARBATO, EMANUELE;
2003

Abstract

OBJECTIVES: We sought to investigate the vascular mechanisms of dobutamine-induced myocardial ischemia. BACKGROUND: Dobutamine stress is often used as a surrogate for exercise. The effects of dobutamine on the epicardial arteries are incompletely understood and possibly different from those of physical exercise. METHODS: Intravenous (IV) dobutamine (40 μg/kg per min) was administered in 19 patients with normal, 23 patients with mildly atherosclerotic, and 12 patients with stenotic coronary arteries. In another two groups of patients with stenotic arteries, IV dobutamine was preceded by 1) an intracoronary (IC) bolus of the alpha-adrenergic blocker phentolamine (12 μg/kg, n = 12); and 2) an IC infusion of the nitric oxide substrate L-arginine (150 μmol/l per min for 20 min, n = 11). Intravenous saline instead of dobutamine was infused into eight patients with normal arteries. After dobutamine (or saline), an IC bolus of isosorbide dinitrate (ISDN, 0.2 mg) was given. Coronary vasomotion was evaluated by quantitative coronary angiography on angiograms obtained after each dose of dobutamine, saline, phentolamine, L-arginine, and ISDN. RESULTS: Dobutamine increased the rate-pressure product and heart rate similarly in all patients except those who received saline. Dobutamine induced vasodilation in normal (change in luminal diameter [ΔLD] vs. baseline: 19 ± 2%) and in mildly atherosclerotic arteries (ΔLD: 8 ± 2%, p < 0.05 vs. normal). In stenotic arteries, dobutamine did not induce significant vasomotion (ΔLD: -3 ± 3%); the latter was improved by L-arginine (ΔLD: 10 ± 3%, p < 0.05 vs. stenotic arteries) and fully restored by phentolamine (ΔLD: 19 ± 3%, p < 0.05 vs. stenotic arteries). CONCLUSIONS: Endothelial dysfunction and enhanced alpha-adrenergic tone contribute to the loss of dobutamine-induced vasodilation in coronary atherosclerosis. In contrast to physical exercise, dobutamine does not induce "paradoxical vasoconstriction" of atherosclerotic coronary arteries. © 2003 by the American College of Cardiology Foundation.
2003
Effects of Intravenous Dobutamine on Coronary Vasomotion in Humans / Barbato, Emanuele; Bartunek, J; Wyffels, E; Wijns, W; Heyndrickx, Gr; De Bruyne, B.. - In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. - ISSN 0735-1097. - 42:9(2003), pp. 1596-1601. [10.1016/j.jacc.2003.03.001]
File in questo prodotto:
File Dimensione Formato  
1) Barbato_JACC2003.pdf

solo utenti autorizzati

Tipologia: Documento in Post-print
Licenza: Dominio pubblico
Dimensione 1.81 MB
Formato Adobe PDF
1.81 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/648931
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 45
  • ???jsp.display-item.citation.isi??? 36
social impact